In a report released today, Chad Messer from Needham maintained a Buy rating on Esperion (ESPR), with a price target of $134.00. The company’s shares closed last Tuesday at $25.59, close to its 52-week low of $23.90.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.5% and a 44.4% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $45.13 average price target, a 76.4% upside from current levels. In a report issued on April 26, Credit Suisse also initiated coverage with a Buy rating on the stock with a $45.00 price target.
See today’s analyst top recommended stocks >>
Esperion’s market cap is currently $720.5M and has a P/E ratio of -5.00. The company has a Price to Book ratio of -7.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
